Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

Flame Biosciences gave up on its IL-1ß inhibitor last fall after Novartis’ asset in the class failed multiple studies. To save itself, the biotech is selling to Leap Therapeutics.

Not in the foreground of the picture? The IL-1ß inhibitor, known as FL-101. Instead, Leap’s buyout focuses on anti-Claudin18.2 antibody...

Click to view original post